• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

China Evergrande fears consume investors awaiting trading

September 21, 2021 by David Barret Leave a Comment

September 21, 2021

NEW YORK/BOSTON/HONG KONG (Reuters) – Anxiety over the prospect of China Evergrande Group defaulting on its mountain of debt gripped investors on Tuesday ahead of two repayment deadlines, with much still unknown about the potential risks to banks in China and global markets.

A major test comes this week, with Evergrande due to pay $83.5 million in interest relating to its March 2022 bond on Thursday. It has another $47.5 million payment due on Sept. 29 for March 2024 notes.

Both bonds would default if Evergrande fails to settle the interest within 30 days of the scheduled payment dates.

Global markets were rattled on Monday as investors worried about the potential impact a default could have on the wider economy, dumping Chinese property stocks and seeking refuge in safe-haven assets.

Evergrande’s shares tumbled another 10% on Monday after Chinese regulators warned that its $305 billion in liabilities could lead to widespread losses in China’s financial system if its debts were not stabilised.

“I think (Evergrande’s) equity will be wiped out, the debt looks like it is in trouble and the Chinese government is going to break up this company,” Andrew Left, founder of U.S.-based Citron Research and one of the world’s best known short-sellers, told Reuters.

“But I don’t think that this is going to be the straw that breaks the global economy’s back,” Left said.

Left in June 2012 published a report that said Evergrande was insolvent and had defrauded investors.

Citi analysts in a research note dated Tuesday said regulators may “buy time to digest” Evergrande’s non-performing loan problem by guiding banks not to withdraw credit and extend the interest payment deadline.

Those analysts said there was “mounting investor concern about potential risk spillover” from Evergrande’s debt crunch, considering the potential liquidity drain for private developers due to increased difficulty in obtaining bank credit, and the contagion effect in the banking sector as they expect around 40.7% of China banks’ assets are related to the property sector.

Still, Citi said that while Evergrande’s default crunch was a potential systemic risk to China’s financial system, it was not shaping up as “China’s Lehman moment”.

Shares in Evergrande, which has been scrambling to raise funds to pay its many lenders, suppliers and investors, closed down 10.2% at HK$2.28 on Monday, after earlier plummeting 19% to its weakest level since May 2010.

Regulators have warned that its $305 billion of liabilities could spark broader risks to China’s financial system if its debts are not stabilised.

World shares skidded and the dollar firmed as investors fretted about the spillover risk to the global economy. U.S. stocks were sharply lower, with the S&P 500 down nearly 2%. [.N]

In any default scenario, Evergrande, teetering https://ift.tt/3EBZmkX between a messy meltdown, a managed collapse or the less likely prospect of a bailout by Beijing, will need to restructure the bonds, but analysts expect a low recovery ratio for investors.

Michael Purves at Tallbacken Capital Advisors in New York said in a note to clients that China’s foreign currency reserves were “arguably in better shape” now than they had been in the past, in the event Beijing chose to “throw money at Evergrande”.

(Reporting by Svea Herbst-Bayliss, Clare Jim, Tom Westbrook, Alun John and Anshuman Daga; Writing by Megan Davies and Sumeet Chatterjee; Editing by Stephen Coates)

Source Link China Evergrande fears consume investors awaiting trading

David Barret
David Barret

Related posts:

  1. Tennis – Medvedev reaches third straight U.S. Open semi-final
  2. U.S. to discuss path forward on Iran in Paris, Moscow talks
  3. Vatican says to require COVID-19 health pass for residents, visitors
  4. Toast raises IPO price range, providing a Monday bump to fintech valuations

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • “Every Species On The Planet Self-Medicates In Some Way”: How Wild Animals Use Medicine
  • Deepest Complex Ecosystem Ever Discovered 10 Kilometers Below The Sea, 892-Kilometer “Megaflash” Lightning Sets New World Record, And Much More This Week
  • The Life And Death Of David Vetter, The Boy Who Lived His Whole Life In A Bubble
  • Time’s Arrow Within Glass Appears To Go Both Ways, Raising Huge Questions
  • World’s “Oldest Baby” Born From Embryo Frozen In 1994 In New World Record
  • What Can Spain’s “Tunnel Of Bones” Tell Us About The Fate Of Human Species On The Brink Of Extinction?
  • Rhino Horns Go Radioactive As Anti-Poaching Project Gets Off The Ground
  • Manta Rays Officially Get Third New Species – 15 Years After First Suspected
  • “Space Hurricanes” Are Happening At Earth’s Poles – And They Can Affect GPS Signals
  • There Is A Crucial Reason Why We Will Never See The Big Bang Directly With Our Telescopes
  • How Does An MRI Machine Work?
  • Catch A Glimpse Of One Of The World’s Rarest Sharks In Dreamy New Footage
  • A One-Shot Vaccine For HIV Might Actually Be On The Cards
  • Chikungunya Virus Is Spreading In China: As CDC Considers Travel Advisory, Here’s What To Know
  • First-Of-Its-Kind Vagus Nerve Implant Gets FDA Approval As A Therapy For Rheumatoid Arthritis
  • First Time Crystal Made Of “Exotic” Giant Atoms 1,000 times Larger Than Hydrogen
  • Prehistoric Humans Began Eating Tubers 700,000 Years Before Our Teeth Evolved To Do So
  • The World’s Oldest Wild Bird “Surprised” Everyone With A Hatched Chick At 74
  • “Spectacular” New Species Of 40cm Giant Stick Insect May Be Australia’s New Heaviest Insect
  • What Is “Nobel Disease”, And Why Do So Many Prizewinners Go On To Develop It?
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version